Research/Discovery
Pivotal LRA-Funded Research Shared at Annual Rheumatology Meeting

November 15, 2021 The Lupus Research Alliance (LRA) supports research into causes and mechanisms of lupus, and identification of targets supporting the development of new therapies or cures for lupus patients. At this year’s meeting of the American College of Rheumatology (ACR), 17 LRA-funded researchers presented their work to share discoveries with the thousands of […] READ MORE

Promise of Additional Lupus Therapies Highlighted at ACR 2021 Annual Meeting

November 9, 2021 Results of clinical trials testing many existing and potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2021, November 3-9. Bringing you the most relevant news for our lupus community, following are summaries of key research presented at the meeting: New Data on Approved Lupus Treatments […] READ MORE

A “Call to Arms” for the Lupus Community

August 18, 2021 Many lupus patients are at risk for COVID-19 infection because of treatment with corticosteroids and other immunosuppressive medications and will be eligible for booster vaccination. However, there are large gaps in our understanding of who will benefit from the booster vaccines, what strategies will improve response to the vaccine and the best […] READ MORE

Promising New Lupus Treatments Highlighted ACR Annual Meeting

Results of clinical trials testing potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2020. These studies include phase I trials, which test for side effects and a safe dosage; larger phase II trials, which test for effectiveness and further gauge safety; and large phase III trials, which confirm […] READ MORE

Results of Two Voclosporin Trials Presented at Key Medical Meeting

October 22, 2020 Aurinia Pharmaceuticals announced that data taken from a combined analysis of two trials, AURA-LV and AURORA underscored the potential for voclosporin to offer a tool to treat lupus nephritis. Results from 534 patients from both trials was presented at the American Society of Nephrology Kidney Week 2020 meeting by Dr. Brad Rovin, […] READ MORE

Lupus Redfined: You Make The Difference

October 22, 2020 Great event; I learned a lot and will have a discussion with my doctor about participating in a trial. It was excellent, and the website is very easy to use. I learned that the medicines you take for lupus are not designed for the disease while the ones  you take in a […] READ MORE

LRA Pleased to Share News of Lupus Nephritis Clinical Trial Launch

October 1, 2019 The Lupus Research Alliance is pleased to share news about the launch of EQUALISE, a Phase 1b trial that will evaluate the safety and tolerability of an experimental compound itolizumab at various doses in a small group of patients with systemic lupus erythematosus (SLE) and lupus nephritis. Sponsored by the biotechnology company […] READ MORE

FDA Expedites Existing Drug Gazyva for Lupus Nephritis

September 18, 2019 The LRA is pleased to share that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to obinutuzumab (Gazyva®) for adults with lupus nephritis – the most common complication of lupus.  The FDA’s designation aims to  speed up  the development and review of drugs intended to treat a serious condition […] READ MORE

VALUE Study Results Reported at EULAR

MADRID, Spain. June 13, 2019 – Results of the first clinical trial sponsored by the Lupus Research Alliance and conducted through its Lupus Clinical Investigators Network (LuCIN) were presented today at the European Congress of Rheumatology (EULAR) 2019.  Entitled VAlidation in LUpus of an Electronic Patient Reported Outcomes Tool (VALUE), the study showed that a […] READ MORE

A Promising New Therapy

April, 2019 As our name implies, the Lupus Research Alliance aims to forge partnerships and bring other players  to the table to better understand and treat lupus — and our latest venture holds the promise of a new therapy. We — and our affiliate, Lupus Therapeutics — are about to collaborate with Takeda Pharmaceutical Company […] READ MORE

Learn and connect with our community!